Navigation Links
Pacira Pharmaceuticals, Inc. Reports Third Quarter 2011 Financial Results
Date:10/31/2011

PARSIPPANY, N.J., Oct. 31, 2011 /PRNewswire/ -- Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX), an emerging specialty pharmaceutical company, today announced financial results for the third quarter ended September 30, 2011 and provided an update on the U.S. Food and Drug Administration's (FDA) approval of EXPAREL™ (bupivacaine liposome injectable suspension) and the commercial strategy to support the product launch.

"With the broad postsurgical pain management label granted by the FDA, we are well positioned to execute our commercial strategy for EXPAREL," said Dave Stack, president and chief executive officer of Pacira Pharmaceuticals, Inc. "Over the past several months, our entire organization has diligently focused on completing the pre-commercial activities necessary to prepare EXPAREL for launch. During this time, we have strengthened our relationships with clinicians and hospitals, presented data demonstrating the efficacy, safety and utility of EXPAREL and completed retrospective health outcomes studies highlighting the economic benefits of reducing opioid use in postsurgical pain management regimens. With these accomplishments as a platform, we believe we are on track for a successful hospital launch of EXPAREL in January 2012, focused on abdominal soft tissue surgeries typically performed by colorectal surgeons, general surgeons and OB/GYNs."

EXPAREL Commercial StrategyThe company has previously announced its intention to launch EXPAREL into the broad hospital market in early 2012.  By the time of launch, Pacira expects to have achieved the following:

  • Final analysis of its retrospective health outcomes research studies, which demonstrate that in certain patient populations, opioid-based pain management often leads to patient care and economic challenges. The first of these data sets will be presented at the American Society of Health
    '/>"/>

  • SOURCE Pacira Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress
    2. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Hernia Repair Presented at the Postgraduate Assembly in Anesthesiology (PGA)
    3. Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment
    4. Pacira Pharmaceuticals Announces FDA Acceptance of EXPAREL™ New Drug Application for Pain Management
    5. Pacira Pharmaceuticals Presents New Data from EXPAREL Phase 3 Study at Orthopaedic Research Societys 57th Annual Meeting
    6. Pacira Pharmaceuticals, Inc. Announces Pricing of Its Initial Public Offering
    7. Pacira Pharmaceuticals Highlights Additional Safety Data on EXPAREL™ for Postsurgical Pain Relief at 2011 American Academy of Orthopaedic Surgeons Annual Meeting
    8. Pacira Pharmaceuticals EXPAREL™ Data to be Featured at 2011 ASCPT 112th Annual Meeting
    9. Pacira Pharmaceuticals to Present at the Barclays Capital 2011 Global Healthcare Conference
    10. Pacira Pharmaceuticals Reports Fourth Quarter and 2010 Financial Results
    11. Pacira Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/3/2015)... 3, 2015  VirtualScopics, Inc. (NASDAQ: VSCP ... solutions, announced today, they are collaborating with a ... philanthropic, epidemiology study partnering with the Ministry of ... has teamed up with a cardiac sonographer to ... results will be used to identify children with ...
    (Date:9/3/2015)... SEATTLE , Sept. 3, 2015  Omeros Corporation ... filed patent infringement lawsuits against Par Pharmaceutical, Inc. and ... the U.S. District Court for the District of ... District Court for the District of Delaware ... Act for Par,s infringement of three Omeros patents, U.S. ...
    (Date:9/3/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/hs5hvr/investigation ... "Investigation Report on China Tamsulosin Market, 2010-2019" ... with other a1- adrenergic receptor blockers, tamsulosin hydrochloride ... risk of urinary tract infections and therefore is ... in 1993 in Japan , ...
    Breaking Medicine Technology:VirtualScopics, Inc. Collaborates with Large Pharmaceutical Company on a Philanthropic, Epidemiology Study in Africa 2VirtualScopics, Inc. Collaborates with Large Pharmaceutical Company on a Philanthropic, Epidemiology Study in Africa 3VirtualScopics, Inc. Collaborates with Large Pharmaceutical Company on a Philanthropic, Epidemiology Study in Africa 4Omeros Files Infringement Suits Against Par 2Omeros Files Infringement Suits Against Par 3Omeros Files Infringement Suits Against Par 4China Tamsulosin Market Investigation Report 2015 2
    ... Holdings, Inc. (NYSE and SIX: ZMH), a global leader ... in the 2011 Morgan Stanley Global Healthcare Unplugged Conference ... September 13, 2011, at 9:10 a.m. Eastern Time. ... be accessed via Zimmer,s Investor Relations website at ...
    ... Sept. 1, 2011 Hill-Rom Holdings, Inc., (NYSE: ... management presentation at the Morgan Stanley Global Healthcare Conference ... 8:35 a.m. ET. You are invited to ... at http://ir.hill-rom.com/events.cfm or access it directly at ...
    Cached Medicine Technology:Zimmer Holdings to Present at 2011 Morgan Stanley Global Healthcare Unplugged Conference 2
    (Date:9/3/2015)... ... September 03, 2015 , ... ... and Navigant Center for Healthcare Research and Policy Analysis has found physician leadership ... , While 47 percent of respondents said their organizations conduct some kind ...
    (Date:9/3/2015)... Tamarac, FL (PRWEB) , ... September 03, 2015 ... ... of the Florida Companies to Watch for 2015 by economic development ... one of only 50 companies in the state selected for this prestigious award, ...
    (Date:9/3/2015)... ... September 03, 2015 , ... Advice columnist, professional life ... debut book, “Stop Wasting Your Time Blaming Others for Your Life.” , Released ... to overcoming life’s obstacles by taking full responsibility for one’s life shares 15 ...
    (Date:9/3/2015)... ... September 03, 2015 , ... For the second ... Annual Inc. 5000 list of fastest-growing private companies in America. President and ... the nation's companies have demonstrated such remarkably consistent high growth, particularly in the ...
    (Date:9/3/2015)... ... September 03, 2015 , ... According to an Oncology Nurse Advisor ... may help patients with oropharyngeal cancer (oral cancer) to be successfully diagnosed and treated ... caused by HPV infections, which have a high rate of success in treatment and ...
    Breaking Medicine News(10 mins):Health News:Survey finds growing movement for physician leadership training 2Health News:Survey finds growing movement for physician leadership training 3Health News:IQ Formulations Hailed Among Florida Companies to Watch for 2015 2Health News:IQ Formulations Hailed Among Florida Companies to Watch for 2015 3Health News:Popular Advice Columnist Shares Her Path to Overcoming Personal Trials in Debut Book 2Health News:Popular Advice Columnist Shares Her Path to Overcoming Personal Trials in Debut Book 3Health News:Inc. 5000 Includes Intellicure, Inc., Two Years in a Row 2Health News:LA Periodontists Discuss Study on Post-Treatment Oral Rinses Used to Test Recurrence of Oral Cancers 2Health News:LA Periodontists Discuss Study on Post-Treatment Oral Rinses Used to Test Recurrence of Oral Cancers 3
    ... Sept. 5 Edwards Lifesciences,Corporation (NYSE: EW ... heart valves,today announced that it has received CE ... SAPIEN transcatheter aortic heart valve,technology with the RetroFlex ... heart valve is implanted via a,minimally-invasive procedure, without ...
    ... ALEXANDRIA, Va., Sept. 5 Traditional Latin,American foods have ... these foods that have brought families together for generations ... health. Oftentimes Latin foods are prepared with high-calorie ... According to the American Diabetes,Association (ADA), eating foods high ...
    ... Inc. (NYSE: WPI ), a leading specialty pharmaceutical,company, ... Food and Drug,Administration (FDA) product approval at its Goa, ... to seek FDA approval to,manufacture additional solid dosage products ... expected to be producing over 1 billion tablets,and capsules ...
    ... Stahl Cowen Crowley LLC, of Chicago,IL, counsel to ... that Dana Corporation, Inc. has entered into a settlement,agreement ... to,benefits. Dana had sought Bankruptcy Court approval to terminate ... result of the settlement Stahl,Cowen Crowley negotiated on behalf ...
    ... Brings Over 20 Years Of Experience ... in Sales, Marketing And Operational Excellence, LENEXA, Kan., ... ) announced the appointment of Thomas Kelly,Mann as chief ... than 20 years with 3M,s healthcare information technology,division where ...
    ... PICK: Immunosuppressive drugs are a double-edged sword to type ... caused when immune cells attack and destroy the insulin ... changed the life of type I diabetics, they neither ... was hoped that islet transplantation would provide a cure, ...
    Cached Medicine News:Health News:Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve 2Health News:Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve 3Health News:Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve 4Health News:Top Tips to Enjoy Healthy Latin Food Without Losing the Taste (Recipe) 2Health News:Top Tips to Enjoy Healthy Latin Food Without Losing the Taste (Recipe) 3Health News:Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility 2Health News:Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee 2Health News:Mediware Names Thomas K. Mann Chief Executive Officer 2Health News:JCI table of contents: Sept. 4, 2007 2Health News:JCI table of contents: Sept. 4, 2007 3Health News:JCI table of contents: Sept. 4, 2007 4Health News:JCI table of contents: Sept. 4, 2007 5Health News:JCI table of contents: Sept. 4, 2007 6Health News:JCI table of contents: Sept. 4, 2007 7Health News:JCI table of contents: Sept. 4, 2007 8Health News:JCI table of contents: Sept. 4, 2007 9Health News:JCI table of contents: Sept. 4, 2007 10Health News:JCI table of contents: Sept. 4, 2007 11Health News:JCI table of contents: Sept. 4, 2007 12
    ... and Maximum ACT introducers represent the ... hemostasis introducers in the world. They ... introducers for use in interventional cardiology ... stenting, atherectomy, temporary pacing, endomyocardial biopsies, ...
    ... hemostasis introducers provide outstanding insertion ... dilator-to-sheath transitions, high kink resistance ... dual layer sheath cannula provides ... works with an extra strong ...
    Bx VELOCITY Coronary Stent with HEPACOAT...
    A steerable diagnostic catheter with optimal maneuverability...
    Medicine Products: